ArticleJournal of nanobiotechnology2022

Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy.

Lipeng Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.